2023
The global prevalence of human fascioliasis: a systematic review and meta-analysis
Infantes L, Yataco G, Ortiz-Martínez Y, Mayer T, Terashima A, Franco-Paredes C, Gonzalez-Diaz E, Rodriguez-Morales A, Bonilla-Aldana D, Barahona L, Grimshaw A, Chastain D, Sillau S, Marcos L, Henao-Martínez A. The global prevalence of human fascioliasis: a systematic review and meta-analysis. Therapeutic Advances In Infectious Disease 2023, 10: 20499361231185413. PMID: 37434654, PMCID: PMC10331341, DOI: 10.1177/20499361231185413.Peer-Reviewed Original ResearchHuman fascioliasisHigh prevalenceGlobal prevalenceSystematic reviewTropical diseasesLarger study sample sizeFollowing inclusion criteriaRandom-effects modelAppropriate diagnostic methodologyHigher prevalence estimatesWorld Health OrganizationRetrospective cohortCase seriesPooled prevalenceSignificant morbiditySubgroup analysisDisease burdenPrevalence proportionsClinical trialsJBI SUMARIWorldwide prevalenceStudy sample sizeInclusion criteriaMethodological qualityGeneral population
2021
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 873.e1-873.e13. PMID: 34052505, PMCID: PMC8478722, DOI: 10.1016/j.jtct.2021.05.016.Peer-Reviewed Original ResearchConceptsConditioning regimen intensityAllo-HCTRegimen intensityChronic graftTransplant characteristicsGraft failureOverall survivalPatient ageSubgroup analysisDynamic International Prognostic Scoring System scoresSystematic reviewAllogeneic hematopoietic cell transplantationInternational Prognostic Scoring System scoreCurative therapeutic modalityNon-relapse mortalityTransplant-related mortalityMedian patient ageOutcomes of patientsSecondary graft failureCo-primary outcomesHematopoietic cell transplantHematopoietic cell transplantationRandomized clinical trialsHeterogeneity of patientsRandom-effects model